ConductScience.org, home

Paper20194151

Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma.

Madan S and 8 others. Mayo Clin Proc, 2010. Cited by 77 papers, by iCite.

Cite this record

ConductScience Library. Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma. Papers, record 20194151. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20194151

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma.
PubMed
Journal
Mayo Clin Proc
PubMed
Year
2010
PubMed
Publication types
Comparative Study, Journal Article, Research Support, N.I.H., Extramural
PubMed
Citations, by iCite
77
iCite
Relative citation ratio, by iCite
2.06
iCite
Revised in PubMed
2021-10-20
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Madan SSumit
2Dispenzieri AAngela
3Lacy MQMartha Q
4Buadi FFrancis
5Hayman SRSuzanne R
6Zeldenrust SRSteven R
7Rajkumar SVS Vincent
8Gertz MAMorie A
9Kumar SKShaji K

Source PubMed

Download CSV of authors

Topics19

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AmyloidosisMajor topic
Antineoplastic AgentsMajor topic
Immunoglobulin Light ChainsMajor topic
Multiple MyelomaMajor topic
Peripheral Blood Stem Cell TransplantationMajor topic
Aged
Aged, 80 and over
Biopsy
Diagnosis, Differential
Dose-Response Relationship, Drug
Female
Follow-Up Studies
Humans
Male
Middle Aged
Prospective Studies
Survival Rate
Treatment Outcome
United States

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
P01 CA062242NCI NIH HHSUnited StatesP01CA062242PubMed and NIH
CA 62242NCI NIH HHSUnited StatesP01CA062242PubMed and NIH

Source NIH RePORTER

Download CSV of grants

References21

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
11582977Diagnostic criteria of multiple myeloma.Hematol Oncol Clin North Am1992https://conductscience.org/library/papers/1582977PubMed
216198646Clinical aspects of systemic amyloid diseases.Biochim Biophys Acta2005https://conductscience.org/library/papers/16198646PubMed
318648809Multiple myeloma-associated amyloidosis is an independent high-risk prognostic factor.Ann Hematol2009https://conductscience.org/library/papers/18648809PubMed
416715110Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted?Bone Marrow Transplant2006https://conductscience.org/library/papers/16715110PubMed
512780789Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.Br J Haematol2003https://conductscience.org/library/papers/12780789PubMed
67878478Primary systemic amyloidosis: clinical and laboratory features in 474 cases.Semin Hematol1995https://conductscience.org/library/papers/7878478PubMed
79674753Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients.Br J Haematol1998https://conductscience.org/library/papers/9674753PubMed
89573002Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients.Blood1998https://conductscience.org/library/papers/9573002PubMed
911856795A long-term study of prognosis in monoclonal gammopathy of undetermined significance.N Engl J Med2002https://conductscience.org/library/papers/11856795PubMed
1012036853Autologous stem cell transplantation for primary systemic amyloidosis.Blood2002https://conductscience.org/library/papers/12036853PubMed
119402328Incidence and impact of light chain associated (AL) amyloidosis on the prognosis of patients with multiple myeloma treated with autologous transplantation.Leuk Lymphoma1997https://conductscience.org/library/papers/9402328PubMed
1216011989Multicentre versus single centre approach to rare diseases: the model of systemic light chain amyloidosis.Amyloid2005https://conductscience.org/library/papers/16011989PubMed
139554527Primary systemic amyloidosis with delayed progression to multiple myeloma.Cancer1998https://conductscience.org/library/papers/9554527PubMed
1416571879Prevalence of monoclonal gammopathy of undetermined significance.N Engl J Med2006https://conductscience.org/library/papers/16571879PubMed
1518162215Amyloidosis: 2008 BMT Tandem Meetings (February 13-17, San Diego).Biol Blood Marrow Transplant2008https://conductscience.org/library/papers/18162215PubMed
1612515719Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL).Blood2003https://conductscience.org/library/papers/12515719PubMed
1715070667Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation.Blood2004https://conductscience.org/library/papers/15070667PubMed
1815180858Guidelines on the diagnosis and management of AL amyloidosis.Br J Haematol2004https://conductscience.org/library/papers/15180858PubMed
1916044444
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.
Am J Hematol2005https://conductscience.org/library/papers/16044444PubMed
209578896The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement.QJM1998https://conductscience.org/library/papers/9578896PubMed

See all 21 referencesDownload CSV of references

Cited by45

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 77 citations.

PMIDTitleJournalYearIn PapersSource
42488491Cardiac amyloidosis risk across ethnoracial and clinical subgroups: a five-year national study.Am J Cardiovasc Dis2026https://conductscience.org/library/papers/42488491PubMed
42454121The value of speckle tracking echocardiography in early identification of subclinical cardiac involvement in patients with multiple myeloma: a pilot retrospective study.Front Med (Lausanne)2026https://conductscience.org/library/papers/42454121PubMed
42305798Real-World Diagnostic Workup of Patients Suspected for Light Chain Amyloidosis and Wild-Type Transthyretin Amyloid Cardiomyopathy: A Retrospective Cohort Study Using US Electronic Health Records.EJHaem2026https://conductscience.org/library/papers/42305798PubMed
41994108Risk of AL Amyloidosis is Associated with Degree of Free Light Chain Elevation and Duration of Exposure.Res Sq2026https://conductscience.org/library/papers/41994108PubMed
41664246The impact of cardiac amyloidosis on patients with multiple myeloma: a systematic review and meta-analysis.Cardiooncology2026https://conductscience.org/library/papers/41664246PubMed
41291170Amyloid Light Chain Proteins in Cardiovascular Disease: Pathogenesis and Emerging Therapies for Cardiac Amyloidosis.Pharm Res2025https://conductscience.org/library/papers/41291170PubMed
41233352Oligomeric cystatin C supports the immunosuppressive activity of myeloid cells through interaction with inhibitory receptors.Signal Transduct Target Ther2025https://conductscience.org/library/papers/41233352PubMed
40650957Recent developments in systemic light-chain amyloidosis prognosis and treatment.Future Cardiol2025https://conductscience.org/library/papers/40650957PubMed
40631729Cardiac amyloidosis detection from a single echocardiographic video clip: a novel artificial intelligence-based screening tool.Eur Heart J2025https://conductscience.org/library/papers/40631729PubMed
40475717Prevalence of Atrial Fibrillation and Intervention Therapy in Cardiac Amyloidosis.Rev Cardiovasc Med2025https://conductscience.org/library/papers/40475717PubMed
39598451Predicting Structural Consequences of Antibody Light Chain N-Glycosylation in AL Amyloidosis.Pharmaceuticals (Basel)2024https://conductscience.org/library/papers/39598451PubMed
39587494Light-chain amyloidosis with concomitant symptomatic myeloma (CRAB-SLiM features): clinical characteristics, cytogenetic abnormalities, and outcomes.BMC Cancer2024https://conductscience.org/library/papers/39587494PubMed
39540049A review of recent clinical trials to evaluate disease-modifying therapies in the treatment of cardiac amyloidosis.Front Med (Lausanne)2024https://conductscience.org/library/papers/39540049PubMed
39476401Mexican position paper for the diagnosis and treatment of cardiac amyloidosis.Arch Cardiol Mex2024https://conductscience.org/library/papers/39476401PubMed
38283805An overview of multiple myeloma: A monoclonal plasma cell malignancy's diagnosis, management, and treatment modalities.Saudi J Biol Sci2024https://conductscience.org/library/papers/38283805PubMed
37909849B-cell maturation antigen chimeric antigen receptor-T therapy alleviated heart failure in patients with multiple myeloma.ESC Heart Fail2024https://conductscience.org/library/papers/37909849PubMed
37511893AL Amyloidosis and Multiple Myeloma: A Complex Scenario in Which Cardiac Involvement Remains the Key Prognostic Factor.Life (Basel)2023https://conductscience.org/library/papers/37511893PubMed
37381778Amyloidogenic light chains impair plasma cell survival.Haematologica2023https://conductscience.org/library/papers/37381778PubMed
37206101CMR left ventricular strains beyond global longitudinal strain in differentiating light-chain cardiac amyloidosis from hypertrophic cardiomyopathy.Front Cardiovasc Med2023https://conductscience.org/library/papers/37206101PubMed
37185672Systemic AL amyloidosis: current approach and future direction.Oncotarget2023https://conductscience.org/library/papers/37185672PubMed

See all 45 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/20194151

GET https://conductscience.org/api/papers/v1/20194151/references?page=2